This video examines a study that used liquid biopsies to monitor disease progression in patients with bladder cancer.
In this video, Emil Christensen, a researcher at Aarhus University Hospital in Denmark, discusses a study that used liquid biopsies to monitor disease progression in bladder cancer patients.
The study examined the feasibility and utility of tracking FGFR3 and PIK3CA hotspot mutations in patients’ urine and plasma. Two patient cohorts were studied: one included patients with non–muscle invasive disease, the other included those with muscle-invasive disease.
The results of the study were presented at the 2017 American Association for Cancer Researcher (AACR) Annual Meeting, held April 1–5 in Washington, DC.